Share-based Payment Arrangement, Expense of Apogee Therapeutics, Inc. from 31 Dec 2022 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Apogee Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2022 to 30 Sep 2025.
  • Apogee Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $11,877,000, a 103% increase year-over-year.
  • Apogee Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $41,956,000, a 134% increase year-over-year.
  • Apogee Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $23,332,000, a 282% increase from 2023.
  • Apogee Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $6,103,000, a 185% increase from 2022.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Apogee Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $41,956,000 $11,877,000 +$6,038,000 +103% 01 Jul 2025 30 Sep 2025 10-Q 10 Nov 2025 2025 Q3
Q2 2025 $35,918,000 $11,344,000 +$5,646,000 +99% 01 Apr 2025 30 Jun 2025 10-Q 11 Aug 2025 2025 Q2
Q1 2025 $30,272,000 $11,126,000 +$6,940,000 +166% 01 Jan 2025 31 Mar 2025 10-Q 12 May 2025 2025 Q1
Q4 2024 $23,332,000 $7,609,000 +$5,398,000 +244% 01 Oct 2024 31 Dec 2024 10-K 03 Mar 2025 2024 FY
Q3 2024 $17,934,000 $5,839,000 +$4,334,000 +288% 01 Jul 2024 30 Sep 2024 10-Q 10 Nov 2025 2025 Q3
Q2 2024 $13,600,000 $5,698,000 +$4,585,000 +412% 01 Apr 2024 30 Jun 2024 10-Q 11 Aug 2025 2025 Q2
Q1 2024 $9,015,000 $4,186,000 +$2,912,000 +229% 01 Jan 2024 31 Mar 2024 10-Q 12 May 2025 2025 Q1
Q4 2023 $6,103,000 $2,211,000 01 Oct 2023 31 Dec 2023 10-K 03 Mar 2025 2024 FY
Q3 2023 $1,505,000 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q3 2023 $0 01 Aug 2023 31 Aug 2023 10-Q 10 Nov 2025 2025 Q3
Q2 2023 $1,113,000 01 Apr 2023 30 Jun 2023 10-Q 12 Aug 2024 2024 Q2
Q1 2023 $1,274,000 01 Jan 2023 31 Mar 2023 10-Q 13 May 2024 2024 Q1

Apogee Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $23,332,000 +$17,229,000 +282% 01 Jan 2024 31 Dec 2024 10-K 03 Mar 2025 2024 FY
2023 $6,103,000 +$3,961,000 +185% 01 Jan 2023 31 Dec 2023 10-K 03 Mar 2025 2024 FY
2022 $2,142,000 04 Feb 2022 31 Dec 2022 10-K 05 Mar 2024 2023 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.